95: Early, Upstream, and Consistent Antithrombotic Therapy in High Risk Non-ST-Elevation ACS: Should Bivalirudin Be Initiated in the ED Prior to Coronary Angiography?

Abstract

In the ACUITY trial, the use of bivalirudin (BIV) resulted in superior net clinical outcomes when compared to combination therapy with either unfractionated heparin or enoxaparin plus a glycoprotein inhibitor (H+GPI) in patients with moderate-high risk non-ST-elevation acute coronary syndromes (NSTE ACS). In the early upstream management of patients with high-risk NSTE ACS, the comparison of a consistent antithrombotic regimen from presentation to coronary angiography with H+GPI, BIV+GPI or BIV alone has not been evaluated.